Rockwell Medical Says Phase 3 CRUISE Data Accepted as Late-Breaking Trial Abstract

Rockwell Medical, Inc. RMTI, a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that the Phase 3 CRUISE-1 and CRUISE-2 clinical abstract submitted as a Late-Breaking Clinical Trial (LBCT) to the ASN LBCT subcommittee has been accepted for poster presentation at the ASN Kidney Week 2013 Annual Meeting, November 7-10 in Atlanta, GA. The abstract will be presented under the Late-Breaking Posters as "Continuous, Maintenance Iron Therapy Using Soluble Ferric Pyrophosphate Citrate Chelate (SFP, Triferic(TM)) Infusion via Hemodialysate in CKD-HD: Phase III CRUISE Studies". The Company will provide further information, including date, time and presenter prior to the ASN annual meeting taking place November 7-10 in Atlanta, GA.